On July 19, Gloenhi announced that on July 19, 2024, the company received a notice of resumption of production from its subsidiary Ningxia Senxuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Ningxia Senxuan"). Ningxia Senxuan has completed the rectification and organized experts to pass the inspection. After various competent authorities organized experts to verify the situation of production suspension and rectification of Ningxia Senxuan, Ningxia Senxuan has orderly resumed its production.
During this shutdown, Ningxia Senxuan actively cooperated with the relevant competent departments and conducted comprehensive rectification and self-inspection of ecological environment protection in accordance with national laws, regulations, regulations, and norms under the supervision and guidance of relevant departments. It also cooperated with the relevant work of the local government departments, prepayment the environmental restoration deposit of 2.5 million yuan, and formulated follow-up plans for safety production and market maintenance. The company requires its holding subsidiary Jiangsu Senxuan Pharmaceutical Co., Ltd. and Ningxia Senxuan to strengthen on-site environmental protection and safety management, strictly implement various safety and environmental protection regulations and systems, further optimize safety production plans, and fully organize production and operation work after the resumption of production of Ningxia Senxuan.